Status:
COMPLETED
Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Lead Sponsor:
Jennifer Keiser
Collaborating Sponsors:
National Institute of Public Health, Vientiane, Laos
Conditions:
Strongyloides Stercoralis Infection
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
PHASE3
Brief Summary
This study is a phase 2, blinded and randomized clinical trial. The phase 2a trial is single blinded and conducted in Lao, while the phase 2b trial is double-blinded and conducted in Lao and Cambodia....
Detailed Description
This is a phase 2a single-blinded and a phase 2b double-blinded randomized clinical trial, which aims to determine efficacy and safety of (2a) seven ascending oral moxidectin dosages in 210 adults inf...
Eligibility Criteria
Inclusion
- Adults (≥ 18 years) infected with S. stercoralis
- Absence of major systemic illnesses
- Written informed consent signed by individual
Exclusion
- Any abnormal medical conditions or chronic disease
- Negative diagnostic result for S. stercoralis
- No written informed consent by individual.
- Pregnant and lactating women.
- Recent use of anthelmintic drug (within past 4 weeks), attending other clinical trials during the study
- Known allergy to study medications (i.e. moxidectin, ivermectin)
- Currently taking medications with known interaction (i.e. for warfarin)
Key Trial Info
Start Date :
November 27 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2021
Estimated Enrollment :
617 Patients enrolled
Trial Details
Trial ID
NCT04056325
Start Date
November 27 2019
End Date
April 30 2021
Last Update
December 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institute of Public Health
Vientiane, Laos